GKOS Jul 2024 62.500 call
- Zacks
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
- Zacks
Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?
Glaukos (GKOS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- Business Wire
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
ALISO VIEJO, Calif., June 14, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with certain holders of its 2.75% Convertible Senior Notes due 2027 (the "Existing Convertible Notes"). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of $230 million princi
